Alimentary Pharmacology & Therapeutics
Fecha de publicación: 13 September 2020
DOI: https://doi.org/10.1111/apt.15998
Autores: Hajir Ibraheim,Samantha Baillie,Mark A. Samaan,Hamzah Abu‐Sbeih,Yinghong Wang,Nicholas J. Talley,Michael P. Jones,Nick Powell
Background: Immune checkpoint inhibitors have revolutionised cancer treatment, but at the cost of off‐target immune‐mediated organ damage. This includes checkpoint inhibitor‐induced enterocolitis which frequently requires hospitalisation and may be life‐threatening. Empiric treatment typically includes corticosteroids and infliximab, although no large‐scale studies have confirmed their effectiveness.
Leer más
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.